In the News
AAIC: A Pill to Slow Down Alzheimer’s Is About Two Years Away
beingpatient.com
AAN 2023: ALZ-801 for Alzheimer’s found to improve cognition in trial
Alzheimer's News Today
The New Era of Life Sciences
Newsweek
Press Releases
Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease
Early, Sustained and Statistically Significant Reduction in Plasma P-tau181 Reaching 31% at 24 Months Observed in Carriers of One or Two Copies of APOE4 Gene, who Represent Two Thirds of Alzheimer’s Patients
Alzheon Raises $100 Million Series E Financing Round to Advance Development and Commercialization of Oral Tablet ALZ-801/Valiltramiprosate for Treatment of Alzheimer’s Disease
Proceeds Will Support Completion of Pivotal APOLLOE4 Phase 3 Study Evaluating ALZ-801/Valiltramiprosate and Regulatory Filings for Patients with Early Alzheimer’s Disease in 2024
Alzheon Announces Appointment of Renowned Biopharma Executive Gino Santini to Board of Directors
Mr. Santini’s Extensive Global Commercial and Business Development Experience Strengthens Alzheon’s Board Leadership
Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease
APOLLOE4 Phase 3 Trial Subjects Who Completed 78 Weeks of Treatment Offered Enrollment in Long-Term Extension Study to Provide Insights into Effect of ALZ-801
Alzheon Announces that United States Federal Circuit Affirmed Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharmaceutical Technology Co., Ltd.’s Patent on Isotopically Enriched Forms of ALZ-801/Valiltramiprosate
U.S. Federal Circuit Affirmed Without Discussion Final Decision of U.S. Patent Office Invalidating Risen (Suzhou) Pharma Tech’s U.S. Patent No. 10,472,323 on Isotopically Enriched Forms of [...]
Peer-Reviewed Scientific Publication Proposes Unifying Single Toxin Theory of Brain Neurodegeneration that Identifies New Drug Targets and Treatments for Alzheimer’s Disease and Other Neurodegenerative Disorders
Soluble Beta Amyloid Aggregates Called Oligomers or Protofibrils Initiate and Drive Pathogenesis of Alzheimer’s Disease All Other Biochemical Effects and Neurodegenerative Changes Observed in Alzheimer’s Brain [...]